Teva to sell Ranbaxy drug in US

Ranbaxy Laboratories on Thursday announced that Teva Pharmaceuticals, under a mutual agreement with the Indian pharma major, has commercially launched its Quinapril HCL tablets in the US.

The product, manufactured by Ranbaxy, would be sold in the US under the Teva label and marketed by Teva USA, a company release said.

As per the agreement, Israel-headquartered Teva would distribute the product and the two companies would have share in the profit.

The launch follows Teva's relinquishment of its right to a 180-day period of marketing exclusivity for Quinapril HCL tablets (5mg, 10 mg, 20 mg and 50 mg), it added.

Quinapril, which has an annual sale of about $55 million, is the AB-rated generic equivalent of Parke Davis' anti-hypertensive agent Accupril tablets.